Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 244 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Rheumatoid Arthritis (RA) Clear all
Terminated Phase 2 Interventional Results available

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

NCT01264770
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Fostamatinib and placebo injections, Adalimumab and placebo of fostamatinib, Placebo of fostamatinib, fostamatinib, and placebo injections
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
40
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Jul 23, 2026, 6:23 AM EDT
Active, not recruiting Not applicable Interventional

Long Term Extension of Safety and Efficacy of Vagus Nerve Stimulator in Patients With Rheumatoid Arthritis (RA)

NCT04862117
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
SetPoint Medical Neurostimulation of the Cholinergic Anti-inflammatory Pathway System
Device
Lead sponsor
SetPoint Medical Corporation
Industry
Eligibility
22 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
4
States / cities
Aventura, Florida • Zephyrhills, Florida • Great Neck, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Jul 23, 2026, 6:23 AM EDT
Terminated Phase 2 Interventional

BG9924 in Combination With Methotrexate for Participants With Active Rheumatoid Arthritis

NCT00458861
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
BG9924, Placebo Comparator
Biological · Other
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Jul 23, 2026, 6:23 AM EDT
Completed No phase listed Observational

A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish Database

NCT05421442
View directory record Official record
Conditions
Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
38,396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Lawrenceville, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 3 Interventional Results available

Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA)

NCT02115750
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Etanercept, CHS-0214
Drug
Lead sponsor
Coherus Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
647 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
37
States / cities
Phoenix, Arizona • Jonesboro, Arkansas • Anaheim, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Tranilast in Patients With Active Rheumatoid Arthritis (RA)

NCT00882024
View directory record Official record
Conditions
Active Rheumatoid Arthritis
Interventions
Tranilast, Placebo
Drug
Lead sponsor
Nuon Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
9
States / cities
Mesa, Arizona • Paradise Valley, Arizona • La Jolla, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2011 · Synced Jul 23, 2026, 6:23 AM EDT
Completed No phase listed Observational

Use of Thermal and 3D Imaging to Quantify Arthritis

NCT01044823
View directory record Official record
Conditions
Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis
Interventions
3D and thermal imaging
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
4 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2017 · Synced Jul 23, 2026, 6:23 AM EDT
Active, not recruiting Phase 2 Interventional

A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)

NCT07176390
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Tulisokibart, Placebo, Methotrexate
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
16
States / cities
Glendale, Arizona • Mesa, Arizona • La Palma, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 23, 2026, 6:23 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)

NCT00476996
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Leflunomide, Methotrexate, Ocrelizumab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
836 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
144
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 116 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2019 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 1 Interventional

Study to Evaluate SC Route of Administration of Ofatumumab in RA Patients

NCT00686868
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
placebo, ofatumumab
Other · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Anniston, Alabama • Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2017 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 3 Interventional Results available

Phase IIIB Subcutaneous Missed Dose Study

NCT00533897
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
13
States / cities
Los Angeles, California • Trumbull, Connecticut • Sarasota, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 2 Interventional Results available

A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone

NCT02066389
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 100 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
12
States / cities
Hemet, California • DeBary, Florida • Venice, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 1 Interventional

Phase 1b Study of PLX5622 in Rheumatoid Arthritis Patients Who Are Receiving Methotrexate

NCT01329991
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
PLX5622, Placebo
Drug
Lead sponsor
Plexxikon
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
4
States / cities
Anniston, Alabama • Lansing, Michigan • Duncansville, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2012 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Not applicable Interventional Results available

Inflammation and Insulin Resistance in Rheumatoid Arthritis

NCT00763139
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 12, 2014 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 4 Interventional Results available

Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis

NCT02831855
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550, Methotrexate, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
694 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
59
States / cities
Huntsville, Alabama • Gilbert, Arizona • Peoria, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 2 Interventional Results available

Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA

NCT04247815
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
ATI-450, Placebo oral tablet, Methotrexate
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Anniston, Alabama • Tampa, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Jul 23, 2026, 6:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sputum Studies of Anti-Citrullinated Protein Antibodies (ACPA) and Rheumatoid Arthritis (RA) Origins

NCT04474392
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
N/A (Observational Study)
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
340 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)

NCT00254293
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept or Placebo (both as IV & SC solution), Abatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
5
States / cities
Orlando, Florida • Atlanta, Georgia • New Orleans, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2014 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 3 Interventional Results available

Phase IIIB Subcutaneous Abatacept Monotherapy Study

NCT00547521
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
abatacept, Methotrexate (MTX)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
15
States / cities
Huntsville, Alabama • Mobile, Alabama • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2015 · Synced Jul 23, 2026, 6:23 AM EDT
Recruiting Not applicable Interventional

ConsideRAte Study - Splenic Stimulation for RA

NCT05003310
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Active Stimulation, Sham Stimulation, Baricitinib, Background Treatment
Device · Drug
Lead sponsor
Galvani Bioelectronics
Industry
Eligibility
22 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
12
States / cities
Anniston, Alabama • Covina, California • Whittier, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Jul 23, 2026, 6:23 AM EDT
Recruiting Phase 1 Interventional

Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA

NCT07237659
View directory record Official record
Conditions
SLE (Systemic Lupus), RA - Rheumatoid Arthritis
Interventions
NTR1011
Drug
Lead sponsor
Neutrolis
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
7
States / cities
Apple Valley, California • Beverly Hills, California • Covina, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 3 Interventional Results available

A Rheumatoid Arthritis Study in Participants

NCT01202760
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
LY2127399, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,004 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
77
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Peoria, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Jul 23, 2026, 6:23 AM EDT
Terminated Phase 3 Interventional Results available

A Study in Participants With Rheumatoid Arthritis

NCT01202773
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
LY2127399, Placebo Q4W, Placebo Q2W
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
110
States / cities
Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 107 more
Source: ClinicalTrials.gov public record
Updated May 13, 2018 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Fostamatinib in Subjects With Impaired Kidney Function

NCT01245790
View directory record Official record
Conditions
Rheumatoid Arthritis, Renal Impairment
Interventions
fostamatinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 15, 2011 · Synced Jul 23, 2026, 6:23 AM EDT